Announcements

by AvalancheInfographics. Explore more visuals like this one on the web's largest information design community - Visually.

April 8, 2014 - A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect –within 24 hours—and was well tolerated in patients with treatment-resistant major depressive disorder. This is the first study ...

The Harrington Scholar-Innovator Award recognizes physician-scientists throughout the U.S. whose research has the potential to change standard of care. The Award provides clinical research funding as well as non-financial support to selected investigators and their institutions to help bridge the gap between basic discovery and clinical introduction. Up to 10 Harrington ...

March 31, 2014 - Erik Lium, PhD, a 16-year veteran with an extensive background in the academic, technology and medical sectors, has been named Vice President and Executive Director of Mount Sinai Innovation Partners, which facilitates the real-world application and commercialization of Mount Sinai discoveries and the development of research ...

Harlem Biospace(Hb) is a biotech incubator for New York City offering affordable shared wet-lab space for early-stage biotech companies. We have built a centrally located lab outfitted with modern biotech equipment, host unique classes and events, and provide business support – creating a community to turn ideas into inventions that ...

 February 18, 2014- DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and the Icahn School of Medicine at Mount Sinai announced today that they entered into a research collaboration agreement to investigate the efficacy and mechanism of epicutaneous tolerance utilizing Viaskin® ...

February 11, 2014 - The Icahn School of Medicine at Mount Sinai today announced the launch of a more accurate carrier screening test for spinal muscular atrophy (SMA), one of the most common and severe autosomal recessive disorders. This new test will help prospective parents more effectively identify whether they carry ...

Conduits Experimental Therapeutics & Technology (ET&T) Program, Tisch Cancer Institute (TCI) and Mount Sinai Innovation Partners (MSIP) Jointly Announce – Request for Applications in Cancer-Related Projects –   Mount Sinai's Conduits ET&T Program, TCI and MSIP are jointly soliciting applications for pilot projects with start date of April 1, 2014. ...

Neurodegenerative diseases represent one of the most difficult classes of diseases for which to develop drugs, yet the need is great with nearly 36 million people currently suffering from Alzheimer’s disease and related dementias worldwide. There are many different pathways that influence neurodegenerative disease progression, offering a huge opportunity to ...